Uncovering Tumour Heterogeneity through PKR and nc886 Analysis in Metastatic Colon Cancer Patients Treated with 5-FU-Based Chemotherapy

Uncovering Tumour Heterogeneity through PKR and nc886 Analysis in Metastatic Colon Cancer Patients Treated with 5-FU-Based Chemotherapy

Colorectal cancer treatment has advanced over the past decade. The drug 5-fluorouracil is still used with a wide percentage of patients who do not respond. Therefore, a challenge is the identification of predictive biomarkers. The protein kinase R (PKR also called EIF2AK2) and its regulator, the non...

Full description

Bibliographic Details
Main Authors: María Belén Ortega-García, Alberto Mesa, Elisa L.J. Moya, Beatriz Rueda, Gabriel Lopez-Ordoño, Javier Ángel García, Verónica Conde, Eduardo Redondo-Cerezo, Javier Luis Lopez-Hidalgo, Gema Jiménez, Macarena Peran, Luis J. Martínez-González, Coral del Val, Igor Zwir, Juan Antonio Marchal, María Ángel García
Format: Article
Language:English
Published: MDPI AG 2020-02-01
Series:Cancers
Subjects:
colorectal cancer
5-fluorouracil-based chemotherapy
protein kinase pkr
non-coding nc886
ambispective study
cluster of patients
biomarkers
Online Access:https://www.mdpi.com/2072-6694/12/2/379

Internet

https://www.mdpi.com/2072-6694/12/2/379

Similar Items